Here are relevant reports on : cerebral-infarction-therapy-market
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030
The global autoinjectors market, valued at US$1.08 billion in 2023, stood at US$1.40 billion in 2024 and is projected to advance at a resilient CAGR of 13.6% from 2024 to 2030, culminating in a forecasted valuation of US$3.02 billion by the end of the period. Technology advancements in autoinjector devices, such as improved design, the addition of connectivity features for data tracking, Bluetooth connectivity, and dosage reminders, are some of the factors that increase the adoption of autoinjectors and drive market growth.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Biophotonics Market by Application(See-through Imaging, Inside Imaging, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors), Technology(In-vivo, In-vitro), End-use(Diagnostics, Therapeutic, Tests), & Geography - Global Forecast to 2020
The overall market for biophotonics in 2014 was valued at USD 26.26 Billion, which is estimated to reach USD 50.18 Billion by 2020, at a CAGR of 11.5% during the forecast period. This market growth can be attributed to emergence of nanotechnology, significant technological advancements over the last few years and their adoption in the medical sector, increase in the demand for home-based POC devices, aging population, and growing lifestyle diseases.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
Asia Pacific Healthcare Market Outlook – [By Health Indicators (Life Expectancy, Mortality), Disease Burden (Epidemiology, Average Cost Of Therapy), Health System (Infrastructure, Expenditure), Regulatory Landscape] - Analysis & Forecast To 2020
The APAC region showcases diverse healthcare challenges across various countries. These range from improving healthcare access in developing countries of Vietnam to tackling rising diabetes, cancer, and cardiovascular diseases in well developed nations of Japan and Pacific countries. In addition, regions of China and India that lie in between developing and well developed countries are facing increase in diseases burden, problems of poverty, limited access to high quality treatment, and slow increase in disposable income. The APAC Healthcare Market Outlook examines the health indicators and healthcare system across India, China, Japan, Singapore, Indonesia, Thailand, Malaysia, Vietnam, Australia, and New Zealand. The APAC Healthcare Market Outlook is segmented into five broad categories: health status, healthcare system assessment, healthcare regulatory landscape, medical devices infrastructure assessment, hospital chain assessment in top 10 hospitals.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035
The global radioligand therapy market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.2% from 2025 to 2035, culminating in a forecasted valuation of US$10.91 billion by the end of the period. The growth of this market is primarily attributed to factors such as increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, and the rising adoption of PSMA and SSTR PET imaging for patient selection.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Intraoperative Radiation Therapy Market Size, Share & Trends by Technology (Electron IORT, Brachytherapy), Products & Services (Accelerators, Treatment Planning system, Applicators, Afterloaders, Accessories), Application (Breast, Brain, Lung Cancer) & Region - Global Forecast to 2025
The global intraoperative radiation therapy market in terms of revenue was estimated to be worth USD 48 million in 2020 and is poised to reach USD 66 million by 2025, growing at a CAGR of 6.4% from 2020 to 2025. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Gold Nanoparticles Market by Process (Physical, Chemical, Biological), Application (Imaging, Targeted Drug Delivery, Proton Therapy, In-Vitro Assays, Sensors, Probes, Catalysis), End-Use Industry and Region - Global Forecast to 2029
The gold nanoparticles market is expected to grow from USD 0.50 billion in 2024 to USD 1.11 billion in 2029, at a CAGR of 16.3% during the forecast period. Prominent companies include BBI Solutions (UK), Cytodiagnostics Inc (Canada), Fortis Life Sciences, LLC. (US), Meliorum Technologies, Inc (US), TANAKA PRECIOUS METAL GROUP Co., Ltd. (Japan), Merck KGaA (Germany), Nanopartz, Inc (US), CD Bioparticles (US), Nano Labs (India), Nanocs Inc. (US), NanoHybrids (US), Sona Nanotech (Canada), Sisco Research Laboratories Pvt, Ltd. (India), Nanoprobes, Inc (US), American Elements (US), TORSKAL (France), Abcam Limited (UK), Particular GmbH (Germany), Dongguan Sat Nano Technology Material Co., Ltd (China), Nano Flow (Belgium), Strem Catalog (US), Nanorh (India), SkySpring Nanomaterials (US), Aurion (Netherlands), NNCrystal US Corporation (US), and among others.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021
Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region - Global Forecast to 2028
The global continuous renal replacement therapy market, valued at US$1.3 billion in 2022, stood at US$1.4 billion in 2023 and is projected to advance at a resilient CAGR of 8.1% from 2023 to 2028, culminating in a forecasted valuation of US$2.1 billion by the end of the period. Various factors such as rise in worldwide prevalence of AKI, Growing number of ICU patients with AKI and rising incidences of sepsis, and growing clinical advantage of CRRT over intermittent blood purification are factors likely to accelerate the growth of the market.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
